1. Generics Bulletin
  2. >>Business
  3. >>Earnings

ANI Guidance Raise Can’t Stop Stock Price Slump

Another Strong Quarter For ANI Was Overshadowed By Panic Among Investors

 
• By Chloe Kent

Stock prices at ANI Pharmaceuticals dropped 14.8% following its Q3 results announcement, despite a guidance raise from the company, after it noted that competitor supply disruptions seemed to be easing off.

Vector of businessman pushing back against red descending arrow
Stocks slumped 14.8% at ANI following the news that competitor supply disruption is beginning to level off • Source: Shutterstock

From Q4 onward, ANI Pharmaceuticals, Inc. management has projected a step down from the exceptional revenue and margins it has been experiencing in recent quarters, as some of the competitor supply disruptions that have boosted its business begin to ease off. Following this announcement stocks at the company saw a 14.8% slump, a figure which has yet to recover despite a guidance raise and earnings beat from the firm.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.

Samsung Bioepis Grows After US Launches

 
• By Dave Wallace

Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 
• By Urtė Fultinavičiūtė

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.